ORKA — Oruka Therapeutics, Inc. Stock Price, Chart & AI Report

Neutral May 31, 2026 • 14:21 UTC The Motley Fool • Cory Renauer

An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 Million

Carl Dambkowski, Director of Oruka Therapeutics, sold 105,000 shares worth approximately $6.19 million on May 21, 2026, reducing his direct holdings by 58.74%. Despite the significant sale, Dambkowski retains approximately 73,743 shares and derivative securities. The sale was executed through the exercise and immediate sale of vested options. Oruka, a clinical-stage biotech company developing monoclonal antibody therapeutics, has seen its stock surge 407% over the past 12 months following positive clinical trial results for its lead candidate ORKA-001 in psoriasis treatment.

ORKA insider sale biotech monoclonal antibody clinical trial psoriasis stock options immunology

Sentiment note

While the insider sale of 58.74% of direct holdings could signal reduced confidence, the director retained significant equity through remaining shares and derivative securities, maintaining alignment with shareholders. The company's strong 407% stock performance and positive ORKA-001 clinical trial results (63.5% of patients achieved 100% clear skin) provide fundamental support. The sale appears to be a liquidity event from option exercises rather than a loss of confidence indicator.

Positive May 11, 2026 • 21:15 UTC The Motley Fool • Prosper Junior Bakiny

A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried?

Oruka Therapeutics reported strong phase 2a trial results for ORKA-001, showing 63.5% PASI 100 response rates compared to Skyrizi's typical 51%, potentially threatening AbbVie's $17.6 billion psoriasis drug. However, the article argues AbbVie remains a solid long-term investment due to its diverse pipeline, other growth drivers like Qulipta and Botox, and its status as a Dividend King.

ABBV ORKA psoriasis treatment clinical trial results drug competition biotech pharmaceutical dividend stocks

Sentiment note

Demonstrated superior clinical trial results for ORKA-001 with 63.5% PASI 100 response rates versus competitors' ~51%, plus a potentially advantageous once-yearly dosing schedule. Stock up 134% year-to-date reflecting market enthusiasm, though late-stage trial success is not guaranteed.

Positive Apr 28, 2026 • 23:42 UTC GlobeNewswire Inc. • Na

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

Oruka Therapeutics priced an upsized underwritten public offering of 9.66 million shares at $72.50 per share, generating approximately $700.4 million in gross proceeds. The offering is expected to close on or about April 30, 2026, with underwriters granted a 30-day option to purchase up to 1.45 million additional shares.

ORKA public offering monoclonal antibody psoriasis biopharmaceutical clinical-stage capital raise underwritten offering

Sentiment note

The company successfully upsized its public offering from the initially proposed $500 million to $700.4 million, indicating strong investor demand and confidence. The substantial capital raise provides significant funding for clinical development of its monoclonal antibody therapeutics for psoriasis and other inflammatory conditions.

Neutral Apr 27, 2026 • 20:17 UTC Benzinga • Not Specified

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

Oruka Therapeutics (NASDAQ: ORKA), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for psoriasis and inflammatory conditions, announced a proposed $500 million underwritten public offering of common stock and pre-funded warrants. The company also expects to grant underwriters a 30-day option to purchase an additional $75 million in shares. The offering is subject to market conditions and SEC approval.

ORKA public offering monoclonal antibody psoriasis biopharmaceutical underwritten offering pre-funded warrants capital raise

Sentiment note

The announcement of a capital raise is a factual corporate action. While it provides funding for development, it also indicates potential dilution to existing shareholders. The sentiment is neutral as this is a standard financing activity with no indication of positive clinical progress or negative setbacks.

Positive Apr 14, 2026 • 17:00 UTC GlobeNewswire Inc. • Delveinsight

The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight

Over 90 pharmaceutical companies are actively developing more than 100 pipeline psoriasis drugs across various clinical stages. Key players including Takeda, Can-Fite BioPharma, Oruka Therapeutics, and others are advancing promising therapies with novel mechanisms of action such as TYK2 inhibitors and IL-23 inhibitors. Recent developments include positive Phase III results from Alumis and Takeda, and regulatory progress from multiple companies, indicating robust innovation in the psoriasis treatment landscape.

CANF ORKA ALMS TAK psoriasis clinical trials pipeline drugs TYK2 inhibitors

Sentiment note

Announced initiation of EVERLAST-B trial and presented interim Phase I data for ORKA-001 (IL-23p19 antibody) at major dermatology conference, demonstrating continued clinical advancement.